Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Durvalumab (MEDI4736) With or Without Tremelimumab in Patients With Metastatic Castration Resistant Prostate Cancer

NCT02788773 is registered in ClinicalTrials.gov with Canadian Cancer Trials Group as lead sponsor.

NCT NCT02788773
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02788773 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Durvalumab (MEDI4736) With or Without Tremelimumab in Patients With Metastatic Castration Resistant Prostate Cancer
Lead sponsor
Canadian Cancer Trials Group
Phase
Phase 2
Overall status
Completed
Start date
December 15, 2016
Completion date
May 1, 2025
Enrollment
52 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer